ArticleNoro psikiyatri arsivi2026
Evaluation of Sexual Dysfunctions in Substance Use Disorder.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to determine the prevalence of sexual dysfunction (SD) in patients diagnosed with substance use disorder (SUD) and to examine its association with sociodemographic and clinical characteristics. Methods: A total of 176 patients (157 males, 19 females) aged between 18 and 45 years and diagnosed with SUD were included in the study. The patients were divided into three groups: those with single SUD, those with multiple SUD, and those receiving buprenorphine-naloxone (BPN) treatment. Patient information was recorded in a data collection form. Patients were asked to complete the Hospital Anxiety and Depression Scale (HADS). To evaluate sexual functions, the International Index of Erectile Function (IIEF), the Premature Ejaculation Diagnostic Tool (PEDT), and the Arizona Sexual Experiences Scale-Male Version (ASEX-M) were administered to male patients; the Female Sexual Function Index (FSFI), and the Arizona Sexual Experiences Scale-Female Version (ASEX-F) were administered to female patients. Results: Among male patients, the prevalence of erectile dysfunction (ED) was found to be 49.7%, and the prevalence of premature ejaculation (PE) was 48.4%. No significant differences were found between the groups in terms of the prevalence of ED (p=0.970) and PE (p=0.287). Similarly, no significant differences were observed in the scores of IIEF (p=0.957), PEDT (p=0.476), and ASEX-M (p=0.852). In male patients, a negative correlation was identified between the severity of anxiety symptoms and the IIEF subscale scores of overall satisfaction (r=-0.171, p=0.032). Depression symptom severity was negatively correlated with the IIEF total score (r=-0.381, p < 0.001), as well as with the subscale scores of erectile function (r=-0.349, p<0.001), sexual desire (r=-0.228, p=0.004), intercourse satisfaction (r=-0.217, p=0.006), overall satisfaction (r=-0.375, p<0.001), and orgasmic function (r=-0.337, p<0.001). The prevalence of SD among female patients was found to be 78.9%. Conclusion: Sexual dysfunction outcomes were comparable among individuals with single SUD, multiple SUD and those undergoing BPN treatment. Moreover, the negative impact of co-occurring depressive and anxiety symptoms on sexual functioning highlights the need for a multidimensional approach to the assessment and management of sexual health in individuals with SUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.